Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Scientists And Clinicians Meet To Understand "Rain Man"
UQ"s Queensland Brain Institute (QBI) will host a workshop tomorrow Tuesday July 14 for clinicians and scientists seeking to better understand the syndromes associated with a brain development condition made famous in the movie Rain Man.
generic viagra online
Merck Issues Statement On WHO Study Showing First Evidence That Elimination Of River Blindness Is Feasible In Africa
Merck & Co., Inc. issued the following statement in response to study results published today by the World Health Organization offering the first evidence that elimination of the tropical disease river blindness (onchocerciasis) in Africa is feasible with treatment with ivermectin (registered trademark Mectizan®). As the discoverer and manufacturer of Mectizan, Merck decided in 1987 to donate the drug to all who need it for as long as necessary until river blindness is eliminated as a public health problem. The Merck Mectizan Donation Program is one of the longest-running disease-specific drug donation and public/private partnership programs in history.
News of the day
Understanding The Anticancer Effects Of Vitamin D3
The active form of vitamin D3 seems to have anticancer effects. To try and understand the mechanisms underlying these effects, researchers previously set out to identify genes whose expression in a human colon cancer cell line was altered by the active form of vitamin D3. One gene identified in this previous study was CST5, which is responsible for making the protein cystatin D. Now, a team of researchers, at the Consejo Superior de Investigaciones Científicas-Universidad AutÃönoma de Madrid, Spain, and the Universidad de Oviedo, Spain, has studied this protein in detail and determined that it has tumor suppressor activity that likely accounts for some of the anticancer effects of the active form of vitamin D3.
Public Health

In End Of Life Choices, Blacks More Likely To Opt For Life-Sustaining Measures

When faced with a terminal illness, African-American seniors were two times more likely than whites to say they would want life-prolonging treatments, according to a University of Pittsburgh study available online and published in the June issue of the Journal of General Internal Medicine. The study, led by Amber E. Barnato, M.D., M.P.H., associate professor of medical, clinical and translational science and health policy, University of Pittsburgh, was based on interviews and surveys with more than 2,800 Medicare beneficiaries 65 years and older, making it the largest nationally representative sample of U.S. seniors" end-of-life treatment preferences. Overall, the majority of Medicare beneficiaries surveyed preferred not to die in a hospital or to receive life-sustaining measures at the end of life. During interviews, study respondents were asked about their treatment preferences in the event they were diagnosed with a terminal illness and had less than a year to live. More African-Americans (18 percent) than whites (8 percent) reported that they would prefer to die in a hospital. African-Americans (28 percent) also were more likely than whites (15 percent) to report that they would opt for life-prolonging drugs, even if the treatment made them feel worse all of the time. Only 49 percent of African-Americans compared to 74 percent of whites responded that they would want potentially life-shortening palliative drugs (for pain and comfort only). Lastly, when asked whether they would opt for mechanical ventilation to extend their lives for a week, 24 percent of African-Americans said they would, compared to 13 percent of whites. When mechanical ventilation would extend life by one month, this percentage rose to 36 percent in African-Americans, compared to 21 percent in whites. "We collected detailed information about personal and social factors that might explain the relationship between African-Americans and preference for more intensive end-of-life treatment. An overly optimistic view of the ability of mechanical ventilation, a breathing machine, to save lives and return people to their normal activities explained some, but not all, of this difference," said Dr. Barnato. Although the study looked at differences in treatment preferences by race, Dr. Barnato cautions it should not be viewed as an invitation to generalize. "As doctors, we should ask each patient and family about their goals of treatment, then offer the treatments that meet those goals, rather than making assumptions about treatment preferences based on race," she said. The study was funded by the National Institute on Aging. Co-authors include Denise Anthony, Ph.D., Dartmouth College; Jonathan Skinner, Ph.D., and Elliott Fisher, M.D., M.P.H., Dartmouth Medical School; and Patricia Gallagher, Ph.D., University of Massachusetts. Clare Collins University of Pittsburgh Schools of the Health Sciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009